Empyrean Energy (LON: EME) has come to an agreement with Conrad Asia Energy to resolve its dispute over the Duyung PSC and Mako gas field in Indonesia. First gas could be in the fourth quarter of 2027. A special purpose vehicle will be established to own these investments, and Empyrean Energy will own 8.5%. After this Empyrean will pay $353,000 to Conrad and a further $353,000 will be paid out of dividends from the special purpose vehicle. Empyrean’s secured convertible note will be restructured, and the lender will be paid out of dividends from the project. The share price tripled to 0.105p.
Artemis Resources (LON: ARV) published its quarterly activities report to December 2025. Drilling at the Titan East gold discovery should complete in the current quarter and follow-up diamond drilling will test strike and depth. The company has already announced plans to leave AIM on 13 February. The share price recovered 8.33% to 0.325p.
Video games art outsourcing provider Winking Studios (LON: WKS) expects 2025 revenues to be at least 40% higher than the $31.9m reported in 2024. That is slightly higher than expectations. Organic growth was in mid-to-high single digits. EBITDA is anticipated to be between 7% and 13% ahead of the $4.8m reported in 2024. There are already approximately $34.6m of bookings to be recognised this year. The full year results are due to be announced on 27 February. The share price increased 6.25% to 12.75p.
Investment bank Peel Hunt (LON: PEEL) is trading more strongly than expected in the year to March 2026. No specific figures were announced but the revenues are expected to exceed current consensus of £122.8m, and pre-tax profit should be more than £15m. Revenues will be announced on 1 April. The share price rose 6.07% to 113.5p.
FALLERS
Sensing and measurement technology developer Transense Technologies (LON: TRT) has not been securing new contracts as fast as it hoped. Also, iTrack royalty income is likely to be10% lower than expected at £2m with the total revenues for the group are forecast at £5.2m, down from £5.55m last year. The SAWsense and Translogik businesses should grow revenues by 30%. The company was profitable in the first half and had cash at £1.33m. The interim results will be released on 17 February. The share price slumped 35.6% to 72.5p.
Trading in Aura Energy (LON: AURA) shares continues on AIM but has been suspended on ASX pending a capital raising. Aura Energy is developing the Haggan polymetallic project in Sweden, where the government has overturned the ban on uranium mining. A 20% outside investment in the project values it at A$55m. The share price is 16.7% lower at 10.5p.
Medical device developer RUA Life Sciences (LON: RUA) generated revenues of £6.7m in the 18 months to September 2025 and there was a move into positive EBITDA. The pre-tax loss was slashed from £2.02m to £236,000. Cash was £3.25m at the end of September 2025. Management further hopes to further exploit the company IP. The share price slipped 7.94% to 14.5p.
Allergy Therapeutics (LON: AGY) has appointed Helge Weiner-Trapness as chief strategy officer and Lawrence Allen Wang as independent non-executive director. The share price fell 7.56% to 11p.